Charmacy Pharmaceutical Co., Ltd. — Capital/Financing Update 2016

Jul 26, 2016

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [66 x 54] intentionally omitted <==

CHARMACY PHARMACEUTICAL CO., LTD. 創美藥業股份有限公司

(a joint stock limited liability company incorporated in the People’s Republic of China)

(Stock code: 2289)

POSITIVE PROFIT ALERT

This announcement is made by the Company pursuant to Rule 13.09 of the Listing Rules and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders and potential investors that based on a preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2016 and the existing information available to the Board, it is expected to record a growth of not less than 40% in the Group’s profit attributable to owners of the Company for the six months ended 30 June 2016 as compared to the corresponding period of last year.

The information contained in this announcement is only based on the preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2016 and the existing information available to the Board, and such accounts has not been audited or reviewed by the Company’s auditors or the Audit Committee of the Board and are subject to finalization and adjustments when necessary.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

This announcement is made by Charmacy Pharmaceutical Co., Ltd. (the “ Company ”, together with its subsidiaries, collectively the “ Group ”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “ Listing Rules ”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

– 1 –

The Board (the “ Board ”) of directors of the Company wishes to inform the shareholders of the Company and potential investors that based on a preliminary review of the unaudited management accounts of the Group for the six months ended 30 June 2016 and the existing information available to the Board, it is expected to record a growth of not less than 40% in the profit attributable to owners of the Company for the six months ended 30 June 2016 as compared to the corresponding period of last year. Such expected substantial growth is mainly benefited from (1) increase in sales of goods to retail pharmacy stores; and (2) increase in the overall gross profit margin, which was mainly due to the increase in purchase discount obtained from suppliers as a result of the increase in our sales of goods which we acted as primary distributor.

The Company is still in the process of finalizing the Group’s interim results for the six months ended 30 June 2016. The information contained in this announcement is based only on the preliminary review of the management accounts of the Group and the existing information available to the Board, and such accounts has not been audited or reviewed by the Company’s auditors or the Audit Committee of the Board, and are subject to finalization and adjustments when necessary. The financial information of the Group and other details will be disclosed in the interim results announcement of the Group for the six months ended 30 June 2016. Such announcement is expected to be published in August 2016.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board Charmacy Pharmaceutical Co., Ltd. Yao Chuanglong Chairman

Hong Kong, 26 July 2016

As at the date of this announcement, the executive directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan, Mr. Fan Jianbo and Mr. Lin Zhixiong; the non-executive director of the Company is Ms. You Zeyan; and the independent non-executive directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).

– 2 –